Cardiac Arrhythmia Detection Articles & Analysis
11 news found
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since ...
(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record electro-cardiogram (ECG) data for early detection of cardiac arrhythmias. The ...
Biotres is designed to continuously record ECG data for early detection of cardiac arrhythmias The Biotres addresses the $2 Billion-dollar holter market Biotricity Inc. ...
CardiacSense’s medical watch CE Mark enables continuous, long-term, accurate and comfortable patient monitoring without the need to implant invasive cardiac monitors – a prevalent practice for patients experiencing arrhythmias. ...
The problem of cardiac arrhythmias does not merely affect those in middle age or advanced age. ...
The company is currently conducting several additional multi-site clinical trials in order to receive regulatory approvals including from Israel’s Ministry of Health including for measuring body temperature, respiratory rate, blood pressure and oxygen saturation (SpO2) in the blood as well as detecting additional arrythmias including cardiac arrest at the ...
The agreement was signed with a distributor for the company’s product, which monitors detects fever, respiratory and chronic diseases as well as heart arrhythmias at a uniquely precise level of an ECG device The agreement in India brings CardiacSense’s total backlog to over $60 million. ...
The Caesarian-based company, that develops the only medical wristwatch successfully tested in clinical trials for monitoring and early detection of fever and respiratory diseases, chronic diseases, and arrhythmia disorders on ECG and Capnograph levels of accuracy, announced last month the signing of distribution agreements totaling about 30 million USD. ...
SEATTLE, May 26, 2020 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it received CE mark certification for the 14-Day version of the Carnation Ambulatory Monitor (“CAM”) patch, the industry’s only P-wave centric ambulatory ...
The wearables provide continuous monitoring of the cardiac systems and blood pressure. Supported by traditional electrocardiogram (ECG) verification, what makes the CardiacSense wearable different is that it uses PPG technology (photoplethysmography) that is free of any movement artifacts (which are the Achilles Heel of traditional PPG) to carry out long-term, continuous ...
HCQ has been demonstrated, in certain populations, to prolong the QT interval, resulting in a potentially lethal arrhythmia called Torsades de Pointes. The unique ability of the BardyDx CAM Patch to detect and record low frequency, low amplitude cardiac rhythms is especially valuable in measuring QT intervals and diagnosing Torsades de Pointes. ...